severe asthma pipeline

Aug 18, 2025

“We have inhalers that can save lives in seconds and biologics that can change the course of the disease—so why are millions still wheezing in emergency rooms (ERs)?” A Global Paradox in Respiratory Health Asthma today stands at the intersection of remarkable scientific progress and sobering real-world stagna...

Sep 12, 2022

Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...